| アブストラクト | Background/Objectives: Worldwide, colon cancer is a major cause of cancer-related mortality, with an increasing incidence influenced by genetic, environmental, and lifestyle factors. Despite advances in diagnosis and personalized treatments, challenges remain in improving patient prognosis, particularly in metastatic colorectal cancer (mCRC). Bevacizumab (BEV), a monoclonal antibody, is widely used in colorectal cancer treatment. This study aimed to analyze adverse events associated with BEV compared with other therapies based on data from the EudraVigilance (EV) database. Methods: A descriptive and disproportionality analysis was conducted on signals reported in the EV database related to BEV. The study included comparisons with other antineoplastic treatments, such as chemotherapy, targeted therapy, and immunotherapy. Patient demographics, severity of adverse drug reactions (ADRs), and distribution patterns were analyzed to assess the safety profile of BEV in colorectal cancer treatment. Results: The majority of the signals for BEV were from patients aged 18-64 years (39.42%) and 65-85 years (34.08%). Hypertension, thromboembolism, proteinuria, and gastrointestinal disorders have been the most frequently reported. Serious ADRs, including gastrointestinal perforations, hemorrhage, and arterial thromboembolism, were observed in 93.74% of Individual Case Safety Reports. BEV was associated with a higher likelihood of vascular and endocrine disorders compared with chemotherapy and other targeted therapies. Immunotherapy was linked to increased immunological ADRs, while BEV demonstrated fewer immune-related toxicities. Conclusions: Continuous monitoring is necessary to optimize patient management, particularly in elderly patients or those with cardiovascular comorbidities. Understanding BEV's safety profile allows for better personalization of treatment strategies, minimizing risks while enhancing therapeutic outcomes. |
|---|
| ジャーナル名 | Pharmaceuticals (Basel, Switzerland) |
|---|
| Pubmed追加日 | 2025/4/26 |
|---|
| 投稿者 | Vonica, Razvan Constantin; Butuca, Anca; Morgovan, Claudiu; Pumnea, Manuela; Cipaian, Remus Calin; Frum, Adina; Dobrea, Carmen Maximiliana; Vonica-Tincu, Andreea Loredana; Pacnejer, Aliteia-Maria; Ghibu, Steliana; Batar, Florina; Gligor, Felicia Gabriela |
|---|
| 組織名 | Preclinical Department, Faculty of Medicine, "Lucian Blaga" University of Sibiu,;550169 Sibiu, Romania.;Clinical Department, Faculty of Medicine, "Lucian Blaga" University of Sibiu,;County Clinical Emergency Hospital of Sibiu, 2-4 Corneliu Coposu Str., 550245;Sibiu, Romania.;Department of Toxicology, Drug Industry, Management and Legislation, Faculty of;Pharmacy, "Victor Babes" University of Medicine and Pharmacy, 2nd Eftimie Murgu;Sq., 300041 Timisoara, Romania.;Department of Pharmacology, Physiology and Pathophysiology, Faculty of Pharmacy,;"Iuliu Hatieganu" University of Medicine and Pharmacy, 400349 Cluj-Napoca,;Romania. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/40283938/ |
|---|
